



# Accelerating Scientific Decisions™

to reduce time, cost, and risk associated with the drug discovery process

almost

# 90%

of candidate drugs fail in the first stage of clinical trials, meaning that most trial drugs that passed preclinical testing will never be tested on humans.<sup>1</sup>

ONLY

# 250 out of 10,000

experimental compounds move past preclinical research<sup>2</sup>

Meaning, the likelihood that an experimental compound will move forward is a mere

# .0250%

<sup>3</sup>

THE FDA APPROVED

# ONLY 55

new drugs in 2018<sup>3</sup>



COST IS RISING FOR DEVELOPMENT

# 1

MEDICINE COSTS an average of

# 2.6

billion<sup>5</sup>

CURRENTLY

there are about

# 7,000

medicines

in clinical development globally and

# 74%

have the potential to be first-in-class treatments<sup>4</sup>—but need to make it through preclinical research first



# 75+

drugs in development for NASH



# 250+

drugs in development for obesity



# 200+

drugs in development for cardiovascular disease & stroke

To get organizations to the next phase of drug discovery faster or to prevent unnecessary and costly steps forward,  
**what options do lab directors have?**



## Reduce the time, cost, and risk associated with the drug discovery process

by using nuclear receptor and *in vitro* toxicology solutions from INDIGO.

# 13+

years

of empowering lab directors to make confident decisions about their compounds

HERE'S HOW

# 1

Largest portfolio of cell-based nuclear receptor assays in the world to help you identify compounds with the highest sensitivity and the lowest potential for unwanted effects and off-target responses

# 2

Our kits deliver results in just 24 hours and provide the most comprehensive data for your investment

# 3

Hepatotoxicity is one of the major reasons that drugs can get rejected, and INDIGO has access to optimized human-derived liver cells for *in vitro* testing

# 1,500+


compounds screened\*

# 5,000+

kits provided\*

# 20+

countries served\*



## Our luminescence-based method and proprietary CryoMite™ preservation process



reproducible results lot to lot about the efficacy, potency, and selectivity of your compounds plus comprehensive lab reports that include helpful graphics, summaries, and insights.

## Top 5 Markets Served



Pharma-Biotech



Academic



CROs-Drug Discovery



Environmental



Chemical

## Why labs choose and trust INDIGO

- Largest Portfolio of Nuclear Receptor Assays
- Clear, Reproducible Nuclear Receptor and *In Vitro* Toxicology Results
- Team Committed to Your Study's Success
- Fast Lab Results for Accelerated Decision-Making
- Reliable Science, Platforms, & People

©2019 INDIGO. All rights reserved

For more information, visit [indigobiosciences.com](https://indigobiosciences.com)

### Sources

1. [https://www.oxfordmartin.ox.ac.uk/downloads/academic/Transforming\\_Drug\\_Discovery.pdf](https://www.oxfordmartin.ox.ac.uk/downloads/academic/Transforming_Drug_Discovery.pdf)
2. [https://cpb-us-e1.wpmucdn.com/sites.northwestern.edu/dist/8/665/files/2015/10/Drug\\_RD\\_Brochure-12e7vs6.pdf](https://cpb-us-e1.wpmucdn.com/sites.northwestern.edu/dist/8/665/files/2015/10/Drug_RD_Brochure-12e7vs6.pdf)
3. <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm592464.htm>
4. <http://phrma.org/industryprofile/2018/>
5. <https://catalyst.phrma.org/developing-a-new-drug-is-actually-harder-than-rocket-science>

\* In past three years



# INDIGO

BIOSCIENCES

Nuclear Receptor & *In Vitro* Toxicology Solutions™